omniture
logo
Search
MINGHUI PHARMACEUTICAL (SHANGHAI) LTD.
Media Room

Latest News

rss

Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting

SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharma...

2024-05-08 18:18 5797

Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis

SHANGHAI, HANGZHOU, China and WILMINGTON, Del., Aug. 17, 2023 /PRNewswire/ -- Minghui Pharmaceutica...

2023-08-17 19:00 4159

Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors

SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceut...

2023-06-20 18:30 4618

Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase 1a Healthy Volunteer Study

SHANGHAI and HANGZHOU, China and WILMINGTON, Del., May 23, 2023 /PRNewswire/ -- Minghui Pharmaceuti...

2023-05-23 19:00 4583

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT

* Study met both primary and all key secondary endpoints * Mean percentage change from baseline ...

2023-04-14 19:00 6179